BioStem Technologies Breaks Core Bottleneck in 'Universal' Tissue Regeneration Material, Reports 95% Revenue Surge

Amniotic membrane, as a high-performance regenerative medicine material, can be applied in dozens of medical fields, offering vast market potential. According to research by Apollo Research Reports, the global biological amniotic membrane market reached $3.26 billion in 2022.

In the U.S. bio-amniotic membrane market, BioStem Technologies stands out as a unique company. Its two founders, despite lacking medical backgrounds, creatively addressed multiple bottlenecks, including the low concentration of active ingredients and suboptimal performance associated with lyophilized amniotic membranes.

Andrew Van Vurst, Co-Founder and Chief Operating Officer of BioStem Technologies, is a former U.S. Marine. More than a decade ago, Andrew Van Vurst was diagnosed with a brain tumor. Due to the lack of ideal treatment options, he underwent radiation therapy, which resulted in stroke-like symptoms such as mild paralysis and speech impairments. This experience motivated Andrew Van Vurst to actively seek better therapeutic alternatives and placed great confidence in cell therapies, which were still in their early stages at the time. Like Alice falling down the rabbit hole, Andrew Van Vurst thus embarked on a journey to explore regenerative medicine and cell therapies.

Jason Matuszewski, CEO of BioStem Technologies, earned a degree in mechanical engineering in 2013 and has extensive experience in strategic operational planning and technical project management, having held positions at various companies including SC Johnson and Mazda. His charitable work with the Juvenile Diabetes Research Foundation sparked his passion for biotechnology, leading him to co-found BioStem Technologies with Andrew Van Vurst in 2014.

The entrepreneurial journey of BioStem Technologies’ two founders may seem implausible. Although BioStem Technologies is not yet a leading player in the rapidly evolving field of regenerative medicine, the company has experienced rapid growth. Leveraging the properties of microenvironment activation to promote tissue repair and regeneration, it has already launched multiple regenerative medicine products based on biological amniotic membrane for applications in tissue injury repair, surgical wound care, and ocular surface reconstruction.

The repair and regeneration of human tissues are closely related to microenvironment activation. Here, “microenvironment activation” needs to be explained.

The microenvironment is a collective term for the interstitial fluid and its various components, consisting of the extracellular matrix, cytokines, growth factors, exosomes, small nucleic acids, and local physical properties of the tissue. These components jointly influence the behavior of cells and tissues within the microenvironment and are essential conditions for cell survival.

The development, growth, and repair of tissues largely depend on microenvironmental conditions. The stability of the microenvironment ensures a proper niche for cells to carry out normal biological activities. Abnormalities in its components, including the extracellular matrix, growth factors, and chemokines, can lead to cellular pathological changes. Furthermore, the interaction between the microenvironment and cells is reciprocal; when tissue is injured, the microenvironment generates and reorganizes extracellular matrix components, while the extracellular matrix also regulates cellular activity.

Microenvironment activation refers to the beneficial effects exerted by allografts on the cells and tissues at the implantation site, a mechanism mediated through tissue engineering scaffolds, growth factor delivery, and exosome signaling.

Simply put, the repair and regeneration of human tissues are highly dependent on microenvironmental activation, relying on factors such as growth factors and the extracellular matrix. The amniotic membrane serves as a natural reservoir of growth factors, extracellular matrix components, and anti-inflammatory cytokines, possessing the capacity to promote tissue repair and regeneration; therefore,Biological amniotic membrane holds a significant position in the field of human tissue repair and regeneration.

Amniotic membrane, derived from human placental tissue, is an allogeneic material primarily consisting of three structural layers: the epithelial cells, the basement membrane, and the stromal layer. The epithelial layer contains various growth factors; the basement membrane is composed of type IV and VII collagen fibers (which promote epithelial cell migration), fibronectin, and laminin; while the stromal layer is rich in transforming growth factor-beta (TGF-β), anti-inflammatory factors, anti-angiogenic proteins, and protease inhibitors.

Biological amniotic membrane offers advantages such as wide availability, low cost, minimal immune rejection, and anti-inflammatory and antibacterial properties. Its application in regenerative medicine has spanned over a century, with uses in ocular surface reconstruction, trauma repair, orthopedics, and other fields.

In the field of ophthalmology, biological amniotic membrane plays an irreplaceable role in treating various ocular surface injuries and corneal reconstruction. Many surgical procedures can cause ocular surface damage, corneal epithelial defects, and conjunctival defects. Biological amniotic membrane serves as a scaffold for the repair of corneal and conjunctival epithelium, enabling effective and rapid restoration of the ocular surface. In the trauma repair market, it addresses challenging conditions such as burns, skin ulcers, and diabetic foot ulcers, accelerating healing and inhibiting scar formation. In orthopedics, biological amniotic membrane can be used to repair bone defects, cartilage injuries, and tendon injuries.

Fresh amniotic membranes retain active ingredients to the greatest extent and demonstrate optimal clinical efficacy. Initially, clinical practice relied on fresh amniotic membranes prepared in-house by hospitals; however, this approach lacked standardization, posed significant clinical risks, and could not be widely adopted, thereby substantially limiting the application of amniotic membranes.

There are three key points to the widespread application of biological amniotic membrane products.First, shelf life; second, the retention of core components such as growth factors; and third, sterilization technology.In summary, the goal is to explore processing methods that best preserve the fresh state of the amniotic membrane, and to develop standardized products with extended shelf life and superior performance.

Technologies such as lyophilization and cryopreservation can extend the shelf life of amniotic membranes, but they also entail varying degrees of drawbacks. Specifically, while lyophilized amniotic membranes can be stored at room temperature and transported over long distances—representing a breakthrough in storage methods—they suffer from significant loss of active ingredients and are prone to issues such as protein denaturation and deterioration of various physicochemical properties. Consequently, they cannot fully replace fresh amniotic membrane products.

To address the pain points associated with lyophilized amniotic membrane, BioStem Technologies has developedProprietary Tissue Processing Technology: BioRetain, it can preserve the natural extracellular matrix components, anti-inflammatory cytokines, and growth factors within fresh tissue, ensuring effective tissue repair while extending the product’s shelf life to up to five years with storage at room temperature. Furthermore, the company employs low-dose electron beam terminal sterilization, which effectively eliminates pathogens.

BioStem Technologies has developed a portfolio of biological amniotic membrane products, including VENDAJE, VENDAJE AC, and VENDAJE OPTIC. These products feature antimicrobial properties that help prevent local contamination and moisture loss, and contain a range of growth factors and anti-inflammatory cytokines to effectively promote tissue healing.

VENDAJE is a soft tissue wound repair product developed from biological amniotic membrane derived from placental tissue. VENDAJE AC, composed of the placenta’s amnion and chorion, is also a soft tissue wound repair product. Unlike VENDAJE, VENDAJE AC utilizes a combination of amnion and chorion; compared to amnion alone, this composite yields a thicker product with greater tensile strength and a richer profile of growth factors, making it suitable for treating complex wounds, severe burns, and other clinical scenarios that demand higher-performance healing and repair products.

VENDAJE OPTIC is a biological amniotic membrane for ophthalmic use, designed for ocular surface reconstruction. It can be applied directly to the eye without the need for additional hardware or sutures.

Under U.S. regulations, human cells, tissues, and cellular and tissue-based products (HCT/Ps) that are autologous, minimally manipulated, and intended for homologous use do not require premarket approval but only registration and listing. BioStem Technologies’ VENDAJE, VENDAJE AC, and VENDAJE OPTIC products have all been commercialized.

In the third quarter of 2022, BioStem Technologies reported net revenue of $1.145 million, a 13% year-over-year decrease, with a gross profit of $842,000 and a net loss of $1.742 million.

As of September 30, 2022, BioStem Technologies reported net revenue of $6.082 million for the first nine months of 2022, a year-over-year increase of 95%, primarily driven by the expansion of its distribution network and increased sales of VENDAJE; gross profit was $5.072 million, representing 83% of revenue; operating expenses were $7.031 million, a year-over-year increase of 134%, mainly due to higher personnel and marketing costs; and the net loss was $2.32 million.

BioStem Technologies: Revenue Data for the Third Quarter and the First Nine Months of 2022

In terms of revenue performance, BioStem Technologies, as an emerging player, still lags behind industry leaders, but it demonstrates strong growth momentum. Future opportunities for BioStem Technologies may lie in expanding sales scale, broadening its coverage areas, or strategically positioning innovative bio-amniotic membrane products.

BioStem Technologies’ innovation lies in its creative solution to the problem of activity loss in lyophilized amniotic membrane. However, it is understood that its products cannot completely replace fresh amniotic membrane in clinical use. The incremental growth in the biological amniotic membrane market is driven more by product innovation, including hydrated amniotic membrane, micronized amniotic membrane, and amniotic membrane endoscopy.

Among these, wet amniotic membrane has emerged as one of the most prominent areas of innovation, with domestic companies already making strategic moves in this field. BioStem Technologies independently developed “Ophthalmic Biological Amniotic Membrane,” China’s first wet-form restorative material for ophthalmic use. This bioactive material addresses a wide range of ocular diseases affecting both the ocular surface and the fundus, covering more than 15 application areas. Currently, BioStem Technologies’ wet amniotic membrane products are used in over 300 Grade IIIA hospitals and well-known private chain eye care institutions across China, generating sales revenue of more than RMB 20 million in 2021.